Protecting Healthcare Personnel from Acquiring Ebola Virus Disease

Weber, David J.; Fischer, William A.; Wohl, David A.; Rutala, William A.

doi:10.1017/ice.2015.205

Cited by 15 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst a post-exposure treatment would confer significant public health benefits to communities affected by EBOV, a medical countermeasure would also be of use in the event of laboratory exposure to the virus as has previously occurred, including institutions in the US 51 , Côte d’Ivoire 52 , England 53 and Germany 54 . The recent outbreak in West Africa has also highlighted the nosocomial transmission of this virus to healthcare workers 55 . In addition, EBOV has historically, and in the present day, been listed as a possible agent for bioterrorism 56 .…”

Section: Discussionmentioning

confidence: 99%

Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic

Dowall

Bosworth

Rayner

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Ebola virus (EBOV) is highly pathogenic, with a predisposition to cause outbreaks in human populations accompanied by significant mortality. An ovine polyclonal antibody therapy has been developed against EBOV, named EBOTAb. When tested in the stringent guinea pig model of EBOV disease, EBOTAb has been shown to confer protection at levels of 83.3%, 50% and 33.3% when treatment was first started on days 3, 4 and 5 post-challenge, respectively. These timepoints of when EBOTAb treatment was initiated correspond to when levels of EBOV are detectable in the circulation and thus mimic when treatment would likely be initiated in human infection. The effects of EBOTAb were compared with those of a monoclonal antibody cocktail, ZMapp, when delivered on day 3 post-challenge. Results showed ZMapp to confer complete protection against lethal EBOV challenge in the guinea pig model at this timepoint. The data reported demonstrate that EBOTAb is an effective treatment against EBOV disease, even when delivered late after infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic

Dowall

Bosworth

Rayner

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…41 Consistent use of appropriate PPE with strict adherence to donning and doffing protocols is crucial to preventing acquisition of EVD during patient care. 28,51,52 A key component of reducing HCP risk is proper training in PPE donning and doffing with ongoing training to maintain competency.…”

Section: Epidemiology and Transmissionmentioning

confidence: 99%

New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): Focus on environmental survival and germicide susceptibility

Weber

Sickbert-Bennett

Kanamori

et al. 2019

American Journal of Infection Control

Self Cite

View full text Add to dashboard Cite

“…Detailed recommendations on screening for Ebola among potentially infected returned travelers and management of patients with EVD are available on the CDC Web pages and in published articles. [65][66][67] Given the high volume of diarrhea and vomiting and the potential for fomite transmission, environmental control is a critical issue in the care of an Ebola-infected patient. Ebola virus may persist on steel and plastic surfaces for >7 days.…”

Section: Infection Control Issuesmentioning

confidence: 99%

“…70 Consistent use of appropriate PPE with strict adherence to donning and doffing protocols is crucial to preventing acquisition of EVD during patient care. [65][66][67] A key component of reducing HCP risk is proper training in PPE donning and doffing with ongoing training to maintain competency.…”

Section: Infection Control Issuesmentioning

confidence: 99%

Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9)

Weber

Rutala

Fischer

et al. 2016

American Journal of Infection Control

Self Cite

106

View full text Add to dashboard Cite

Over the past several decades, we have witnessed the emergence of many new infectious agents, some of which are major public threats. New and emerging infectious diseases which are both transmissible from patient-to-patient and virulent with a high mortality include novel coronaviruses (SARS-CoV, MERS-CV), hemorrhagic fever viruses (Lassa, Ebola), and highly pathogenic avian influenza A viruses, A(H5N1) and A(H7N9). All healthcare facilities need to have policies and plans in place for early identification of patients with a highly communicable diseases which are highly virulent, ability to immediately isolate such patients, and provide proper management (e.g., training and availability of personal protective equipment) to prevent transmission to healthcare personnel, other patients and visitors to the healthcare facility.

show abstract

Protecting Healthcare Personnel from Acquiring Ebola Virus Disease

Cited by 15 publications

References 20 publications

Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic

Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic

New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): Focus on environmental survival and germicide susceptibility

Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9)

Contact Info

Product

Resources

About